



Regional Chapter Annual Report - 2015

Chapter	Poland
Region	Europe
President	Joanna Lis, PhD, Assistant Professor; Department of Pharmacoeconomics of Medical University of Warsaw, MA Director at Sanofi
President-Elect	Maciej Niewada, MD, Professor, Department of Clinical & Experimental Pharmacology of Medical University of Warsaw; HEALTHQUEST Company
Past President	Karina Jahnz-Rozyk, Head of Department of Immunology & Allergology Military Institute of Medicine, Warsaw
Secretary	Marcin Czech, MD, Professor, IMS HEALTH
Treasurer	Witold Owczarek, MD, Professor, Department of Dermatology of Military Institute of Medicine, Warsaw
Director	Joanna From
Director	
# Members	170

Describe your Chapter's accomplishments for 2015 with regard to Scientific and Educational activities.

- 1) Quality of Life Special Interest Group of Work on ISPOR Poland Chapter on Dictionary related to drug pricing and reimbursement conditions in Poland. It is a collection of Polish entries with their English counterparts.
2. Patronage on regional journal on health economics: "Journal of Health Policy and Outcomes Research (JHPOR)" issued under the auspices of the Polish Society of Pharmacoeconomics.
3. Work at ISPOR Central & Eastern Europe Network (CEE Network) - active participation in:
 - o ISPOR CEE Network Executive Committee
 - o ISPOR CEE Network Education Committee
 - o ISPOR CEE Network Publication Committee (2013-2015 Chair-Elect Prof. Karina Jahnz-Rozyk, MD Head & Professor, Department of Clinical Immunology & Allergology, Military Institute of Medicine, Poland)
 - o ISPOR CEE Network Research CommitteeActive engagement in current initiatives of CEE Network.
4. Ready for publication of the Polish edition of the ISPOR books: 'ISPOR Taxonomy of Patient Registries: Classification, Characteristics and Terms' - waiting for ISPOR permission



Regional Chapter Annual Report - 2015

Describe your Chapter's accomplishments for 2015 with regard to Policy-related activities.

1. ISPOR Poland Chapter participation in working team on changes of HTA Guidelines in Poland - co-operation with Polish HTA Agency (AOTMiT/AHTAPol)
2. Conferences on "Registry/RWE" and "Pharmacoeconomics in public health" organized by ISPOR Poland Chapter, with participation of representatives of Polish Health Authorities
3. Participation in session of Polish Academy of Science within Drug Therapy Committee - "From registration to reimbursement", Warsaw, 5 Mar 2015
1. XIII International Conference of ISPOR Poland Chapter " Pharmacoeconomics in public health" , Warsaw, 2-4 Dec 2015
2. Participation in session on PARALLEL TRADE: CAN WE CURB THE IMPACT ON CENTRAL & EASTERN EUROPE (CEE) COUNTRIES? at XVII ISPOR at Milano - 7-10 Nov 2015
3. Conference in Poznan "Role of Real World Evidence in pharmacoeconomic studies Conf. Pharmacoeconomics chance to balance the spending in health care, Poznan, 20 Nov 2015
4. II Scientific Conference under auspices of : Journal of Health Policy & Outcomes Research and ISPOR Poland Chapter " Patient Registries: its role in health care system, new trends and hopes for Polish patients" - with mini-session of ISPOR Poland Chapter - 19 March 2015
5. Participation in 5th Adriatic and 4th Croatian Congress of Pharmacoeconomics and Outcomes Research " New targeted treatment as major HC financial challenges in the region" presentation on SWPT analysis of cost per QALY in cancer care reimbursement decisions
- OTHER Chapters's accomplishments: 1. The potential use of observational studies and registries in cardiology for example the study Polkard registers Pacjentów- role in the health system, new trends and hopes for Polish patients, 09.03.2015 r. Warsaw
2. The economic consequences of cancer pain treated unsuccessfully Conf. Pain, Ozarow Mazowiecki, 17 -18.03.2015
3. Cost-effectiveness of innovative therapies for diabetes conference improvements in glycemic control, Brunow 27, Lwówek Śląski, 17-18.04.2015
4. From Pharmacoeconomics and Health Technology Assessment is a clinical decision making in Poland Conf. ISSC, Gdańsk, 25.04.2015
5. The panel of experts Innovations in Health Care, Warsaw, 10.11.2015
6. Pharmacoeconomics treatment of pain. Pharmacoeconomic aspects of the use of formulations of fentanyl for the treatment of breakthrough pain in cancer VI Symposium "Advances in the treatment of pain", Zakopane, 15-17.10.2015
7. The costs of asthma in Poland - analysis of clinical and economical. Lecture given at the Fifth Conference on Bioethics Science and Training, Ethics and economics in medicine -symbioza or conflict, organized by the Institute of Agricultural Medicine on March 25 of 2015.
8. The use of actual data and state registers of patients in Poland. Lecture given at the Krakow Symposium HTA / MA 2015 23-24.06.2015.
- 9.

Describe your Chapter's accomplishments for 2015 with regard to Chapter meetings or conferences.



Regional Chapter Annual Report - 2015

Economic analysis and medical costs of COPD, Watch Health Care 06/01/2015 10. "Role of RWE in HCS in Poland" at X International Symposium of EBHC: "Disinvestment by HTA and Pricing", Krakow, 14-15 Dec 2015 11. QOL in medicine and HTA, Wroclaw, 12 Jun 2015 12.

Describe your Chapter's accomplishments for 2015 with regard to membership engagement.

1. Educational activities within the Scientific Sections of Polish ISPOR Chapter for members of Polish Society of Pharmacoeconomics, which work on specific topics: o Health Technology Assessment o Health-related quality of life o Therapeutic programs, Pharmaceutical Care& Pharmaceutical Law o Epidemiology and cost of illnesses 2. Conferences organized by ISPOR Poland Chapter (see above) 3. Website: www.farmakoekonomika.pl 4. Scientific publications on pharmacoeconomics by ISPOR Poland Chapter's members

Is your Chapter affiliated with any institutions, universities, government or associations (other than ISPOR)? If yes, please list and describe the nature of these affiliations(s).

No
Constitution - Polish Pharmacoeconomics Society



Regional Chapter Annual Report - 2015

Does your Chapter collect membership dues or fees from individuals for local Chapter membership? If yes, how much are the dues?

Yes

\$30 USD, \$10 - Students

How many ISPOR International members (paying dues to ISPOR Headquarters) does your Chapter have? Provide an estimate if you do not have an exact count.

Does your Chapter have any agreements or sponsorship arrangements with any for-profit companies, governments, health authorities or associations? If yes, please describe.

No

Does your Chapter employ paid administrative or management staff (Association Management Company, contracted staff)?

Yes

Other than the page for your Chapter on the ISPOR website, does your Chapter maintain a website?

Yes

www.farmakoekonomika.pl

When did your Chapter last update the ISPOR Chapter Constitution?

In the last 3 years.

Has your Chapter (as a group, not as individual members) submitted formal comments or responses to any government or health authority in 2014 or 2015? If yes, what was the topic or issue?

No

Does your Chapter (as a group, not as individual members) interact in some way with the HTA or other official guidelines in your country? If yes, please name guideline(s) and describe.

Yes

Participation in review of HTA Guidelines

Does your Chapter have any committees or special interest groups? Please indicate and briefly describe.

Yes

1. Health Technology Assessment, 2. Health-related quality of life; 3. Therapeutic programs, Pharmaceutical Care& Pharmaceutical Law 4. Epidemiology and cost of illnesses

Academia %

15

Government/HTA Agency %

5

Industry %

25

Consulting %

25

Clinicians %

10

Student %

15

Other %

5



Regional Chapter Annual Report - 2015

What benefits does your Chapter offers to its members?

- Educations and knowledge exchanges - Focus on new trends in pharmacoeconomics and HTA - Contacts with Health Care System experts - Possibilities to shape of HCS in Poland

What are the most significant achievements of your Chapter in 2015?

- XIII International Conference of ISPOR Poland Chapter : "Pharmacoeconomics in public health" with participation of HC experts and HC decision makers - discussion with Health Authorities in PL on RWE in health technology assessment - readiness to publication into Polish the ISPOR books: 'ISPOR Taxonomy of Patient Registries: Classification, Characteristics and Terms' - member of Team working on updates of Polish HTA Guidelines - active participation of ISPOR Poland Chapter in CEE ISPOR Network

What are the greatest challenges facing your Chapter?

- ISPOR in 2016 - changes of place organization - Better cooperation with Health Authorities towards better understanding of role of pharmacoeconomics and outcomes research in PL

How does your Chapter fulfill ISPOR's mission to promote health economics and outcomes research excellence to improve decision making for health globally? Describe how it supports the development and promotion of the discipline of health economics and outcomes research in your region.

All activities of ISPOR Poland Chapter reported in this survey (see points 4- 6) are linked in promoting health economics and outcomes research. We supports the development and promotion of the discipline of health economics and outcomes research in our region by: 1. Organizing and participating (giving the lectures in specific topics) in scientific conferences on pharmacoeconomics and outcomes research (see previous boxes) 2. Involving in HCS projects in PL and CEE (HTA Guidelines updates, cooperation with Polish HTA Agency, Ministry of Health, etc) 3. Publication of scientific papers on pharmacoeconomics and outcomes research in PL 4. Preparation and publication of Polish editions of ISPOR books: e. g recently 'Therapeutic and Diagnostic Device Outcomes Research' 5. Active participation in ISPOR European and Annual International Congresses and CEE Network activities 6. Promotion of pharmacoeconomics and outcomes research in CEE conferences and meetings (see the list of the main conferences and meetings in previous boxes)

How can the ISPOR organization as a whole (Staff, Board, Consortia, Networks, etc.) better support your Chapter?

Focus on local pharmacoeconomics and outcomes research issues and generalized into global contexts Inviting member of the Chapters to work on global projects Organization of smaller conferences/meetings (but often) on specific topics on pharmacoeconomics and outcomes research

Please indicate who prepared this report, include title, phone, email.

Joanna Lis, PhD, Assistant Professor, Department of Pharmacoeconomics of Medical University of Warsaw and MA Director at Sanofi Poland Mail: Joanna@fraktal.com.pl Phone: +48 607 370 093